4.7 Article

Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 65, Issue 7, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02000-20

Keywords

carbapenem-resistant Enterobacterales; surveillance; Enterobacterales; carbapenem resistant

Funding

  1. AstraZeneca Pharmaceuticals LP
  2. Pfizer, Inc.
  3. Biomedical Advanced Research and Development Authority (BARDA) [HHSO100201500029C]

Ask authors/readers for more resources

The study estimated the incidence of carbapenem-resistant Enterobacterales globally and found that the resistance mechanisms varied by region, with KPC-type, metallo-beta-lactamases, and OXA-48-like beta-lactamases being the main contributors. The overall percentage of meropenem-nonsusceptible Enterobacterales increased from 2012 to 2017, with different carbapenemase types showing increasing proportions in different regions.
To estimate the incidence of carbapenem-resistant Enterobacterales (CRE), a global collection of 81,781 surveillance isolates of Enterobacterales collected from patients in 39 countries in five geographic regions from 2012 to 2017 was studied. Overall, 3.3% of isolates were meropenem-nonsusceptible (MIC >= 2 mu g/ml), ranging from 1.4% (North America) to 5.3% (Latin America) of isolates by region. Klebsiella pneumoniae accounted for the largest number of meropenem-nonsusceptible isolates (76.7%). The majority of meropenem-nonsusceptible Enterobacterales carried KPC-type carbapenemases (47.4%), metallo-beta-lactamases (MBLs; 20.6%) or OXA-48-like beta-lactamases (19.0%). Forty- three carbapenemase sequence variants (8 KPC-type, 4 GES-type, 7 OXA-48-like, 5 NDM-type, 7 IMP-type, and 12 VIM-type) were detected, with KPC-2, KPC-3, OXA- 48, NDM-1, IMP-4, and VIM-1 identified as the most common variants of each carbapenemase type. The resistance mechanisms responsible for meropenem-nonsusceptibility varied by region. A total of 67.3% of all carbapenemase-positive isolates identified carried at least one additional plasmidmediated or intrinsic chromosomally encoded extended-spectrum beta-lactamase, AmpC beta-lactamase, or carbapenemase. The overall percentage of meropenem-nonsusceptible Enterobacterales increased from 2.7% in 2012 to 2014 to 3.8% in 2015 to 2017. This increase could be attributed to the increasing proportion of carbapenemase-positive isolates that was observed, most notably among isolates carrying NDM-type MBLs in Asia/South Pacific, Europe, and Latin America; OXA-48-like carbapenemases in Europe, Middle East/Africa, and Asia/South Pacific; VIM-type MBLs in Europe; and KPC-type carbapenemases in Latin America. Ongoing CRE surveillance combined with a global antimicrobial stewardship strategy, sensitive clinical laboratory detection methods, and adherence to infection control practices will be needed to interrupt the spread of CRE.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available